Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

Alastair Thompson to lead IU’s breast cancer center

Alastair Thompson was named director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center’s Vera Bradley Foundation Center for Breast Cancer Research.

August 07, 2026

Vol.52 No.31

Clinical Roundup

BRCA-negative patients may still be high-risk for breast cancer, study finds

Women who test negative for BRCA gene mutations may still be at greater risk of developing breast cancer than the general population, according to a study led by investigators at Cedars-Sinai Medical Center, the University of Toronto, and the University of Sydney.

August 07, 2026

Vol.52 No.31

Cancer Policy

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

NBCC President Fran Visco authored the following open letter to the House Ways and Means Committee, criticizing the committee for failing to bring the Metastatic Breast Cancer Access to Care Act, HR 2048, before the committee for markup.

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Breast cancers diagnosed during the first three years after childbirth, particularly within the first year, may be biologically more aggressive than similar cancers in women who have never given birth, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

July 10, 2026

Vol.52 No.27

Clinical Roundup

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

For people at high risk of developing breast cancer, yearly mammograms may not be enough to detect tumors early. To make earlier diagnosis easier, a Massachusetts Institute of Technology team has developed portable detectors based on ultrasound, which could be used much more frequently. The team reports that they have improved the resolution of the images produced by their system, making it easier to spot potential tumors, as well as cysts and microcalcifications.

July 10, 2026

Vol.52 No.27

Clinical Roundup

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

MammaPrint + BluePrint can help identify a subset of patients with hormone receptor positive, HER2-negative early-stage breast cancer most likely to benefit from anthracycline-based chemotherapy, according to the results of the prospective FLEX Study (NCT03053193).

July 02, 2026

Vol.52 No.26

Anti-Müllerian hormone may help many women with HR+ breast cancer avoid chemotherapy

YOU MAY BE INTERESTED IN

Alastair Thompson to lead IU’s breast cancer center

BRCA-negative patients may still be high-risk for breast cancer, study finds

NBCC’s open letter to Ways and Means demands markup for Metastatic Breast Cancer Access to Care Act

Young women diagnosed with breast cancer within three years of childbirth may face more aggressive disease, UCLA study finds

Portable ultrasound system could make reliable breast imaging more accessible, MIT study finds

MammaPrint + BluePrint genomic profiling predicts anthracycline chemotherapy benefit in HR+HER2- early-stage breast cancer

Renew today!

Subscriber content

Never miss an issue!

Login